Cargando…

Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants

The SARS-CoV-2 Omicron variant (B.1.1.529) has three major lineages BA.1, BA.2, and BA.3(1). BA.1 rapidly became dominant and has demonstrated substantial escape from neutralizing antibodies (NAbs) induced by vaccination(2–4). BA.2 has recently increased in frequency in multiple regions of the world...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jingyou, Collier, Ai-ris Y., Rowe, Marjorie, Mardas, Fatima, Ventura, John D., Wan, Huahua, Miller, Jessica, Powers, Olivia, Chung, Benjamin, Siamatu, Mazuba, Hachmann, Nicole P., Surve, Nehalee, Nampanya, Felix, Chandrashekar, Abishek, Barouch, Dan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845515/
https://www.ncbi.nlm.nih.gov/pubmed/35169817
http://dx.doi.org/10.1101/2022.02.06.22270533
_version_ 1784651688367357952
author Yu, Jingyou
Collier, Ai-ris Y.
Rowe, Marjorie
Mardas, Fatima
Ventura, John D.
Wan, Huahua
Miller, Jessica
Powers, Olivia
Chung, Benjamin
Siamatu, Mazuba
Hachmann, Nicole P.
Surve, Nehalee
Nampanya, Felix
Chandrashekar, Abishek
Barouch, Dan H.
author_facet Yu, Jingyou
Collier, Ai-ris Y.
Rowe, Marjorie
Mardas, Fatima
Ventura, John D.
Wan, Huahua
Miller, Jessica
Powers, Olivia
Chung, Benjamin
Siamatu, Mazuba
Hachmann, Nicole P.
Surve, Nehalee
Nampanya, Felix
Chandrashekar, Abishek
Barouch, Dan H.
author_sort Yu, Jingyou
collection PubMed
description The SARS-CoV-2 Omicron variant (B.1.1.529) has three major lineages BA.1, BA.2, and BA.3(1). BA.1 rapidly became dominant and has demonstrated substantial escape from neutralizing antibodies (NAbs) induced by vaccination(2–4). BA.2 has recently increased in frequency in multiple regions of the world, suggesting that BA.2 has a selective advantage over BA.1. BA.1 and BA.2 share multiple common mutations, but both also have unique mutations(1) (Fig. 1A). The ability of BA.2 to evade NAbs induced by vaccination or infection has not yet been reported. We evaluated WA1/2020, Omicron BA.1, and BA.2 NAbs in 24 individuals who were vaccinated and boosted with the mRNA BNT162b2 vaccine(5) and in 8 individuals who were infected with SARS-CoV-2 (Table S1).
format Online
Article
Text
id pubmed-8845515
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-88455152022-02-16 Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants Yu, Jingyou Collier, Ai-ris Y. Rowe, Marjorie Mardas, Fatima Ventura, John D. Wan, Huahua Miller, Jessica Powers, Olivia Chung, Benjamin Siamatu, Mazuba Hachmann, Nicole P. Surve, Nehalee Nampanya, Felix Chandrashekar, Abishek Barouch, Dan H. medRxiv Article The SARS-CoV-2 Omicron variant (B.1.1.529) has three major lineages BA.1, BA.2, and BA.3(1). BA.1 rapidly became dominant and has demonstrated substantial escape from neutralizing antibodies (NAbs) induced by vaccination(2–4). BA.2 has recently increased in frequency in multiple regions of the world, suggesting that BA.2 has a selective advantage over BA.1. BA.1 and BA.2 share multiple common mutations, but both also have unique mutations(1) (Fig. 1A). The ability of BA.2 to evade NAbs induced by vaccination or infection has not yet been reported. We evaluated WA1/2020, Omicron BA.1, and BA.2 NAbs in 24 individuals who were vaccinated and boosted with the mRNA BNT162b2 vaccine(5) and in 8 individuals who were infected with SARS-CoV-2 (Table S1). Cold Spring Harbor Laboratory 2022-02-07 /pmc/articles/PMC8845515/ /pubmed/35169817 http://dx.doi.org/10.1101/2022.02.06.22270533 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Yu, Jingyou
Collier, Ai-ris Y.
Rowe, Marjorie
Mardas, Fatima
Ventura, John D.
Wan, Huahua
Miller, Jessica
Powers, Olivia
Chung, Benjamin
Siamatu, Mazuba
Hachmann, Nicole P.
Surve, Nehalee
Nampanya, Felix
Chandrashekar, Abishek
Barouch, Dan H.
Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
title Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
title_full Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
title_fullStr Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
title_full_unstemmed Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
title_short Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
title_sort comparable neutralization of the sars-cov-2 omicron ba.1 and ba.2 variants
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845515/
https://www.ncbi.nlm.nih.gov/pubmed/35169817
http://dx.doi.org/10.1101/2022.02.06.22270533
work_keys_str_mv AT yujingyou comparableneutralizationofthesarscov2omicronba1andba2variants
AT collierairisy comparableneutralizationofthesarscov2omicronba1andba2variants
AT rowemarjorie comparableneutralizationofthesarscov2omicronba1andba2variants
AT mardasfatima comparableneutralizationofthesarscov2omicronba1andba2variants
AT venturajohnd comparableneutralizationofthesarscov2omicronba1andba2variants
AT wanhuahua comparableneutralizationofthesarscov2omicronba1andba2variants
AT millerjessica comparableneutralizationofthesarscov2omicronba1andba2variants
AT powersolivia comparableneutralizationofthesarscov2omicronba1andba2variants
AT chungbenjamin comparableneutralizationofthesarscov2omicronba1andba2variants
AT siamatumazuba comparableneutralizationofthesarscov2omicronba1andba2variants
AT hachmannnicolep comparableneutralizationofthesarscov2omicronba1andba2variants
AT survenehalee comparableneutralizationofthesarscov2omicronba1andba2variants
AT nampanyafelix comparableneutralizationofthesarscov2omicronba1andba2variants
AT chandrashekarabishek comparableneutralizationofthesarscov2omicronba1andba2variants
AT barouchdanh comparableneutralizationofthesarscov2omicronba1andba2variants